Premium
Pharmacokinetic study of cyclosporin A (Sandimmun) in patients with primary biliary cirrhosis.
Author(s) -
Robson S,
Neuberger J,
Keller HP,
Abisch E,
Neiderberger W,
Graffenried B,
Williams R
Publication year - 1984
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1984.tb02517.x
Subject(s) - pharmacokinetics , primary biliary cirrhosis , cmax , bioavailability , medicine , nephrotoxicity , oral administration , creatinine , pharmacology , cirrhosis , area under the curve , half life , gastroenterology , urology , kidney
The pharmacokinetics of cyclosporin A (CS‐A) were studied in 10 patients with primary biliary cirrhosis (PBC) after oral administration in steady state. Mean values for area under the blood concentration‐ time curve (AUC), time to maximal blood concentration (tmax), maximal blood concentration (Cmax) and elimination half‐life (t1/2,z) were similar to results of previous studies in transplant patients. The variation between patients was large. No significant correlations of pharmacokinetic data with biochemical or histological parameters were found. Because of the high variability of pharmacokinetic parameters, patients with PBC treated with CS‐A need to be regularly controlled for nephrotoxicity by estimation of serum creatinine and bioavailability (trough blood levels).